Amazon Launches Bio Discovery — 40+ Bio Foundation Models, AI Agent, Lab-in-the-Loop 🔗

Amazon Web Services launched Amazon Bio Discovery at its Life Sciences Symposium in New York. The platform provides researchers with access to more than 40 biological foundation models — including contributions from Boltz and Profluent, with more from Biohub expected — alongside an AI agent that guides experimental design and model selection. The loop closes in the physical world: Ginkgo Bioworks and Twist Bioscience handle wet lab validation of computationally designed candidates. Bayer and the Broad Institute are among the early adopters. Researchers can upload custom models or integrate third-party tools. The design explicitly targets researchers without extensive computational backgrounds, reducing the barrier to running in-silico experiments at scale.

Two domain-specific drug discovery platforms from two of the largest technology companies in the world, in the same week. The race to own the model layer of drug discovery is now a product race, not a strategic positioning race.

Helical Closes $10M Seed for Virtual AI Lab at Pharma Scale 🔗

London-based Helical has raised $10 million in seed funding led by Redalpine, with participation from Aidan Gomez and Clément Delangue. The company builds infrastructure for translating biological foundation models into reproducible in-silico discovery workflows for pharmaceutical teams. The architecture separates two historically siloed functions: a Virtual Lab for biologists and translational scientists, a Model Factory for ML engineers and data scientists. Current pharma partners include Pfizer on predictive biomarkers and Tanabe Pharma America on neurodegeneration research. The founding thesis: the model is not the bottleneck. The system around the model is.

Tempus AI Deploys Automated Clinical Updates and Shows 31 Abstracts at AACR 2026 🔗

Tempus AI launched an automated clinical update service that keeps cancer treatment recommendations aligned with evolving oncology guidelines without requiring new patient samples. The service runs inside its AI-enabled clinician portal. The company also brought 31 research abstracts to the AACR Annual Meeting 2026 in San Diego — a research footprint that positions Tempus not as a data vendor but as an active contributor to the oncology science that runs through its commercial platform.

Autonomous Lab AI and the Governance Gap 🔗

An analysis published this week in Silicon Republic put a question on the table that the industry has been circling: AI systems can now autonomously design and execute thousands of biological experiments. The collaboration between OpenAI and Ginkgo Bioworks is the primary reference point. The concern is not the technology — it is the accountability frameworks around it, which were not designed for systems operating without a human in the experimental loop. Existing governance was built for human-directed research with AI assistance. Autonomous biology requires a different model.

The Signal: This is the structural next stage of the AI governance problem in life sciences. Previous issues have tracked ungoverned AI tool use inside ELNs and agentic platforms being deployed in regulated clinical workflows. Autonomous experimental design pushes the question further: at what point does an AI-generated experimental hypothesis require documented human sign-off before execution? No regulator has formally answered that yet. The companies that build accountability frameworks before the answer is mandated will be positioned ahead of the requirement rather than scrambling to meet it. That gap is an early-mover opportunity for any software vendor operating in research infrastructure.

Aiforia Becomes Exclusive AI Partner for France's Government-Backed PROSTIA Pathology Project 🔗

Aiforia France has been selected as the AI partner for PROSTIA, a two-year project led by Assistance Publique-Hôpitaux de Paris and funded by Bpifrance under the France 2030 national program. The project expands Aiforia's existing AP-HP collaboration — initiated in 2024 at Bicêtre and Saint-Louis hospitals — to five additional sites, covering all AP-HP pathology departments involved in prostate cancer management. Aiforia's CE-IVD marked prostate cancer diagnostic solution will be deployed across all seven hospitals, enabling AI-assisted analysis of approximately 3,000 biopsy cases per year. The project aims to evaluate the medical, operational, and economic impact of AI integration into routine pathology workflows at scale, with a stated objective of extending the framework to other cancer types in the longer term.

The Signal: The evaluation mandate of PROSTIA carries a specific downstream purpose that makes this project structurally more significant than a typical clinical deployment. The data generated is explicitly intended to inform future decisions on state reimbursement for AI in pathology — meaning a successful outcome does not just validate Aiforia's technology, it could establish the evidence base for national funding of an entire product category across France. For AI pathology vendors operating in Europe, state-backed reimbursement decisions of this kind are the highest-leverage outcome possible: they shift procurement from discretionary hospital budgets to covered clinical infrastructure. France is the largest European market for AI-assisted cancer diagnostics. If PROSTIA delivers, the reference it sets will travel.

European VC Q1 2026: AI Captures More Than Half of All Funding for the First Time 🔗

European venture funding reached $17.6 billion in Q1 2026, up nearly 30% year-on-year, with AI companies accounting for $9.2 billion — the first time AI has exceeded 50% of total European VC on record. Deal volume fell sharply: down 40% overall, down 44% at seed stage. The growth is entirely concentrated in larger rounds for more established companies. Life sciences AI is among the primary drivers of the large-round category.

The Signal: The pattern mirrors what Rock Health documented in US digital health last week: capital concentrating, deal counts falling, the gap between platforms with demonstrated traction and everything else widening each quarter. European early-stage life sciences AI tools that have not yet established proof of commercial deployment are competing for a shrinking share of available seed capital. The funding environment is rewarding maturity and penalising early stage more sharply than at any point in the past four years.